Filing summary
Registrant and period: The supplied filing is Rexahn Pharmaceuticals, Inc.’s unaudited Form 10-Q for the quarter ended September 30, 2011, not an Opus Genetics filing. Rexahn described itself as a development-stage biopharmaceutical company with no commercial product sales.
Financial performance and liquidity
- Revenue: None for the three or nine months ended September 30, 2011 or 2010.
- Net loss: $1.47 million for Q3 2011, versus net income of $0.22 million in Q3 2010; $11.73 million for the first nine months of 2011, versus a restated $11.41 million loss in the comparable 2010 period. Nine-month loss per share was $0.13, compared with $0.15 in 2010.
- Costs: Nine-month R&D expense rose to $10.51 million from $2.45 million, principally reflecting Serdaxin’s Phase IIb trial and preclinical work on RX-3117 and RX-5902. General and administrative expense declined to $2.81 million from $4.42 million. No meaningful operating margin is applicable given the absence of revenue and continued losses.
- Cash flow: Operating cash use was $10.65 million for the first nine months, compared with $4.57 million in 2010. Investing activities used $2.05 million; financing provided $13.58 million. Cash and cash equivalents increased $0.88 million.
- Balance sheet at September 30: Cash and equivalents were $13.22 million, marketable securities $1.95 million, and restricted cash equivalents $2.95 million. The company reported total assets of $18.69 million, total liabilities of $8.52 million, and stockholders’ equity of $10.17 million. Accounts payable and accrued expenses were $3.91 million; warrant liabilities were $3.65 million. The company reported no debt instruments on its balance sheet.
- Funding: Management said cash, restricted cash, and marketable securities totaled $18.11 million and were expected to cover minimum planned operating needs through December 31, 2012. The company nevertheless expected to seek additional financing; its June 2011 shelf registration statement allowed offerings of up to $100 million.
Changes and unusual items
- R&D spending increased sharply year over year, while G&A declined, partly because 2010 included stock compensation for investor-relations services and legal costs related to the Amarex dispute.
- Q3 2011 results included a $1.87 million noncash gain from remeasurement of warrant liabilities. For the first nine months, that gain was $1.99 million, versus a $4.33 million noncash loss in the restated 2010 period. These fair-value changes materially affect reported earnings.
- 2010 comparative results were restated because certain warrants and anti-dilution put features had been incorrectly classified as equity rather than liabilities. The restatement changed reported other income or expense and net income or loss, but did not affect operating loss or operating cash flow.
- Rexahn reclassified amortization of a research and development arrangement from revenue to a reduction of R&D expense; this had no effect on net loss or cash flows.
- Shares outstanding were 95.3 million as of November 9, 2011. The company issued equity in 2011, including a $10 million gross institutional financing in March and a $3.95 million gross investment by Teva in January.
Outlook, programs, and risks
- Serdaxin: Results announced November 4, 2011, after quarter-end, showed no efficacy advantage over placebo in the Phase IIb major-depression trial; the study reported safety and tolerability. Management had not decided whether or how to continue the program and was reassessing resource allocation.
- Other candidates: Archexin’s pancreatic-cancer Phase II trial had completed enrollment, with results anticipated in mid-2012; RX-3117 was in preclinical development, with a possible exploratory early-stage study in Q4 2011. RX-5902 could enter Phase I in the first half of 2012. Plans for Serdaxin’s Parkinson’s study and Zoraxel’s Phase IIb study remained under review.
- Management estimated approximately $0.4 million for Archexin clinical development, $1.9 million to close out the Serdaxin MDD trial, and $3.0 million for Zoraxel’s Phase IIb trial, subject to reprioritization. It also cited expected preclinical-pipeline spending of $5.0 million. The filing states that development costs and timing are uncertain.
- The company anticipated continuing losses and stated it would need additional capital to pursue its plans. If financing is unavailable, it may reduce R&D, beginning with preclinical programs. Key risks include clinical-trial outcomes and delays, regulatory approvals, financing availability, third-party research and manufacturing, market acceptance, and intellectual-property protection.
- Contracted R&D agreements had estimated total costs of $19.91 million, of which $11.43 million had been paid as of September 30; agreements were generally terminable on notice. A $1 million KRICT milestone was contingent on marketing approval and had not been triggered. No legal proceedings were reported.
Most important facts to verify
- Confirm the issuer: this text is Rexahn Pharmaceuticals’ 2011 Form 10-Q, not Opus Genetics’ filing.
- Review the Serdaxin Phase IIb failure and management’s subsequent decisions on the program and related trials.
- Assess whether the stated liquidity runway and financing assumptions support the planned clinical and preclinical spending.
- Examine the warrant-liability valuation assumptions and the 2010 restatement, including the effect of noncash fair-value movements on earnings.
- Track trial milestones, spending commitments, potential dilution from outstanding options and warrants, and any changes in financing availability.